Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma

Thymic carcinoma (TC) is a rare cancer with minimal evidence of survival following palliative‐intent chemotherapy. Sunitinib, everolimus, and pembrolizumab have been proposed as active agents based on previous phase II trials. In this phase II study, TC patients previously treated with platinum‐base...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuma, Yusuke, Goto, Yasushi, Ohyanagi, Fumiyoshi, Sunami, Kuniko, Nakahara, Yoshiro, Kitazono, Satoru, Kudo, Keita, Tambo, Yuichi, Kanda, Shintaro, Yanagitani, Noriko, Horiike, Atsushi, Horinouchi, Hidehito, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamamoto, Noboru, Nishio, Makoto, Ohe, Yuichiro, Hosomi, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571815/
https://www.ncbi.nlm.nih.gov/pubmed/32813912
http://dx.doi.org/10.1002/cam4.3385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571815/
https://www.ncbi.nlm.nih.gov/pubmed/32813912
http://dx.doi.org/10.1002/cam4.3385

Ejemplares similares